MacroGenics to Participate in Upcoming Investor Conference
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at . MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:
羅克維爾，馬里蘭州，2024年12月2日（環球新聞網） -- -- macrogenics, Inc.（納斯達克：MGNX）是一家生物製藥公司，專注於發現、開發、製造和商業化創新的單克隆抗體治療藥物用於癌症治療。今天，公司宣佈管理層將參加本月以下投資者會議：
- 7th Annual Evercore HealthCONx (Coral Gables, FL). MacroGenics' President and Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, December 4, 2024, at 7:30am ET. MacroGenics' management will also participate in one-on-one meetings.
- 第七屆evercore HealthCONx（佛羅里達州科勒爾蓋布爾斯）。macrogenics的總裁兼首席執行官Scott Koenig萬.D., Ph.D.將於2024年12月4日星期三上午7:30（東部時間）參加一個爐邊談話。macrogenics的管理層還將參加一對一會議。
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at . The Company will maintain an archived replay of this webcast on its website for 30 days.
可以在macrogenics網站的投資者關係部分的「事件與演講」中訪問上述演示的網絡廣播。公司將在其網站上保持該網絡廣播的存檔回放30天。
About MacroGenics, Inc.
關於馬科基因公司
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at . MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
macrogenics（公司）是一家生物製藥公司，專注於發現、開發、製造和商業化創新的單克隆抗體治療藥物用於癌症治療。公司主要通過其專有的下一代抗體技術平台生成產品候選管線，這些技術平台在廣泛的治療領域具有應用性。macrogenics的技術平台與蛋白質工程專長的結合使公司能夠生成有前景的產品候選，並與全球藥品和生物技術公司建立若干戰略合作關係。有關更多信息，請訪問公司的官方網站。macrogenics及其macrogenics標誌是macrogenics, Inc.的商標或註冊商標。
###
###
CONTACT: CONTACTS:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172, info@macrogenics.com
聯繫方式：
Jim Karrels，高級副總裁，首席財務官
1-301-251-5172，info@macrogenics.com
譯文內容由第三人軟體翻譯。